Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Metastatic Triple-Negative Breast Carcin...
Phase EARLY_PHASE1
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Drug: Neratinib Oral Tablet — 240mg oral daily. Dosing will follow standard dose escalation procedures
  • Drug: Ruxolitinib Oral Tablet — 20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure

Primary Outcomes

  • Objective Response Rate (18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-09-16
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Baylor Research Institute
Principal Investigators:
  • Joyce A O'Shaughnessy, MD (PRINCIPAL_INVESTIGATOR) - Baylor Scott & White The Heart Hospital
Contact Information
Study Contact:
Page E Blas, MA
214-820-5424
page.blas@bswhealth.org
Page E Blas, MA
214-820-5424
page.blas@bswhealth.org
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
Joyce A O'Shaughnessy, MD
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
Interventions
  • Drug: Neratinib Oral Tablet — 240mg oral daily. Dosing will follow standard dose escalation procedures
  • Drug: Ruxolitinib Oral Tablet — 20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure
Study Locations (1 sites)
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas 75246 United States
Eligibility Criteria
Inclusion Criteria: * A patient will be considered for enrollment in this study if all the following criteria are met: 1. Female patients ≥18 years of age 2. Have a diagnosis of metastatic TNBC previously treated with standard anthracycline, cyclophosphamide, and taxane chemotherapy, unless there was a contraindication to doxorubicin, in which case prior treatment with this agent is not required. Note. TNBC defined as ER-negative tumors with ≤10% tumor nuclei immunoreactivity, or "ER Low Positive" as defined by the updated ASCO/CAP guidelines 2020. 3. Have not received more than 4 prior chemotherapy regimens for metastatic disease. Prior platinum and/or taxane therapy in the adjuvant or metastatic setting is permitted. Patients with more than 4 prior regimens may be allowed on study per physician discretion, if ECOG PS is 0-1. 4. Have locoregional (e.g., breast, chest wall, regional lymphatic) or pulmonary or hepatic metastatic disease that is amenable to core needle biopsy. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted. If a skin biopsy cannot be safely obtained, patients may still be eligible, per physician discretion. 5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 6. Have adequate hematologic function, defined by: 1. Absolute neutrophil count (ANC) \>1500/µL 2. Platelet count ≥100,000/ µL 3. Hemoglobin ≥9 g/dL or ≥5.6 mmol/L 7. Have adequate liver function, defined by: 1. AST and ALT ≤2.5 x the upper limit of normal (ULN) or ≤5 x ULN in presence of liver metastases 2. Total bilirubin ≤1.5 x ULN OR direct bilirubin ≤ULN for patients with total bilirubin levels \>1.5 × ULN 8. Have adequate renal function, defined by: a. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance of ≥30 mL/min 9. Patients who have a history of brain metastasis are eligible for the study provided that all the following criteria are met: 10. Brain metastases which have been treated 11. Off-treatment with steroids before administration of the first dose of treatment 12. No ongoing requirement for dexamethasone or anti-epileptic drugs 13. No clinical or radiological evidence of progression of brain metastases 14. Patients must be accessible for treatment and follow-up. 15. All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry. Exclusion Criteria: * A patient will be ineligible for inclusion in this study any of the following criteria are met: 1. Has received a live vaccine or live-attenuated vaccine within 30 days of the first dose of study treatment. Administration of killed vaccines is allowed. 2. Has peripheral neuropathy ≥grade 2 3. Has completed previous radiotherapy for metastatic disease \<2 weeks prior to study treatment initiation 4. Has an active infection requiring systemic therapy 5. Has significant cardiovascular disease, such as: 1. History of myocardial infarction, acute coronary syndrome, or coronary angioplasty/stenting/bypass grafting within the last 6 months 2. Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV, or history of CHF NYHA class III or IV. 6. Has a known history of active tuberculosis 7. Women who are pregnant or lactating. All patients with reproductive potential must agree to use effective contraception from time of study entry until at least 3 months after the last administration of study drug. 8. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as: 1. severe impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air 2. liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C). 9. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's full participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the Treating Physician. 10. Has received prior systemic anti-cancer therapy within 2 weeks prior to study treatment. 11. Has received investigational agents within 4 weeks prior to study treatment. Monoclonal antibody agents should have a 4-week (28 day) washout period. 12. Any other investigational or anti-cancer treatments while participating in this study 13. Any other active malignancy
Conditions Solid Tumors, ER+ Breast Cancer, Triple ...
Phase PHASE1, PHASE2
Enrollment 102
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: JAB-2485 (Aurora A inhibitor) — Administered orally
  • Drug: JAB-2485 (Aurora A inhibitor) — Administered orally

Primary Outcomes

  • Dose Escalation phase: Number of participants with dose limiting toxicities (DLTs) (First 21 days of Cycle 1)
  • Dose Escalation phase: Number of participants with adverse events (AEs) (Up to 3 years)
  • Dose Expansion phase: Objective Response Rate (ORR) (Up to 3 years from baseline to RECIST confirmed Progressive Disease (PD))
  • Dose Expansion phase: Duration of Response (DOR) (Up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2022-12-20
Completion: 2027-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 102 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.
Contact Information
Study Contact:
Jacobio Pharmaceuticals
(781) 918-6670
clinicaltrials@jacobiopharma.com
Interventions
  • Drug: JAB-2485 (Aurora A inhibitor) — Administered orally
  • Drug: JAB-2485 (Aurora A inhibitor) — Administered orally
Study Locations (8 sites)
Henry Ford Health System, Detroit, Michigan 48202 United States
Washington University, St Louis, Missouri 63110 United States
Mary Crowley Cancer Research, Dallas, Texas 75230 United States
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah 84112 United States
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100101 China
Peking University Third Hospital, Beijing, Beijing Municipality 100101 China
Jilin Cancer Hospital, Changchun, Jilin 130000 China
Shandong Cancer Hospital, Jinan, Shandong 250117 China
Eligibility Criteria
Inclusion Criteria: * Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Must be able to provide an archived tumor sample * Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor * Dose Expansion phase cohorts must meet specific expression or gene mutation where indicated * Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition * Must have at least 1 measurable lesion per RECIST v1.1 * Must have adequate organ functions * Must be able to swallow and retain orally administered medication Exclusion Criteria: * Has central nervous system (CNS) metastases or carcinomatous meningitis, except if CNS metastases treated and no evidence of radiographic progression or hemorrhage for at least 28 days * Active infection requiring systemic treatment within 7 days * Active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV * Any severe and/or uncontrolled medical conditions * left ventricular ejection fraction (LVEF) ≤50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA) * QT interval using Fridericia's formula (QTcF) interval \>470 msec * Experiencing unresolved CTCAE 5.0 Grade \>1 toxicities * Clinically significant eye disorders
Conditions Type 2 Diabetes Mellitus
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to compare carotid intima-media thickness (CIMT) and layer-specific texture characteristics of the carotid wall between individuals with Type 2 diabetes mellitus (T2DM) and normoglycemic controls, to assess the impact of T2DM on these ultrasound variables and evaluate their ability to discriminate between low and high cardiovascular risk at 10 years.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: SCORE2 — Will classify individuals into four cardiovascular risk categories: * For participants aged 50-69 years: * Low-to-moderate risk: \<5% * High risk: ≥5% to \<10% * Very high risk: ≥10% * For participants aged 40-49 years: * Low-to-moderate risk: \<2.5% * High risk: ≥2.5% to \<7.5% * Very high risk: ≥7.5%
  • Diagnostic Test: SCORE2-Diabetes — Will also classify individuals into four risk categories: low (\<5%), moderate (5-10%), high (10-20%), and very high (\>20%).
  • Diagnostic Test: Ultrasound Assessment — Three bilateral longitudinal scans of the common carotid artery will be obtained for carotid intima-media thickness (CIMT) measurement and stratification of carotid wall layers for subsequent texture analysis. Additionally, a bilateral video recording of the same imaging plane containing a minimum of five cardiac cycles will be acquired. One end-diastolic frame per video-corresponding to the relaxed arterial wall-will be selected to standardize image acquisition and CIMT measurement.

Primary Outcomes

  • SCORE2 (baseline)
  • SCORE2 - Diabetes (baseline)
  • Energy or angular second moment (ASM) (baseline)
  • Homogeneity or inverse difference moment (IDM) (baseline)
  • Contrast (CON) (baseline)
  • Textural correlation (TCOR) (baseline)
  • Entropy (ENT) (baseline)
  • Carotid intima-media thickness (CIMT) (baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-25
Completion: 2026-08-02
Eligibility
Age: 40 Years – 69 Years
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cardenal Herrera University
Principal Investigators:
  • FRANCISCO JAVIER MOLINA PAYÁ, PhD (PRINCIPAL_INVESTIGATOR) - CEU CARDENAL HERRERA UNIVERSITY
Contact Information
Study Contact:
SERGIO MONTERO NAVARRO, PhD
+34965426486
sergio.montero@uchceu.es
SERGIO MONTERO NAVARRO
+34 96 542 64 86
sergio.montero@uchceu.es
Francisco Javier Molina Payá
Interventions
  • Diagnostic Test: SCORE2 — Will classify individuals into four cardiovascular risk categories: * For participants aged 50-69 years: * Low-to-moderate risk: \<5% * High risk: ≥5% to \<10% * Very high risk: ≥10% * For participants aged 40-49 years: * Low-to-moderate risk: \<2.5% * High risk: ≥2.5% to \<7.5% * Very high risk: ≥7.5%
  • Diagnostic Test: SCORE2-Diabetes — Will also classify individuals into four risk categories: low (\<5%), moderate (5-10%), high (10-20%), and very high (\>20%).
  • Diagnostic Test: Ultrasound Assessment — Three bilateral longitudinal scans of the common carotid artery will be obtained for carotid intima-media thickness (CIMT) measurement and stratification of carotid wall layers for subsequent texture analysis. Additionally, a bilateral video recording of the same imaging plane containing a minimum of five cardiac cycles will be acquired. One end-diastolic frame per video-corresponding to the relaxed arterial wall-will be selected to standardize image acquisition and CIMT measurement.
Study Locations (1 sites)
Francisco Javier Molina Payá, Elche, Alicante 03204 Spain
Eligibility Criteria
Inclusion Criteria * European adults. * Age between 40 and 69 years. * Confirmed diagnosis of type 2 diabetes mellitus. * No established cardiovascular disease. * Availability of the required clinical and metabolic variables: Age; Sex; Systolic blood pressure; Non-high-density lipoprotein (non-HDL) cholesterol; Smoking status; Duration of diabetes; Glycated hemoglobin (HbA1c); Presence or absence of diabetes-related target organ damage (e.g., albuminuria, retinopathy) Exclusion Criteria * History of clinical cardiovascular disease (secondary prevention). * Type 1 diabetes mellitus. * Patients with established severe target organ damage or conditions that automatically classify them as very high cardiovascular risk according to ESC guidelines. * Advanced chronic kidney disease (estimated glomerular filtration rate \<30 mL/min/1.73 m²).
Conditions Schizophrenia, Forensic Psychiatry, Outc...
Phase Not Applicable
Enrollment 350
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

The DUNDRUM Forensic Redevelopment Evaluation study (D-FOREST study) is a multi-site comprehensive evaluation of a complete National Forensic Mental Health Service. The study will have a prospective, observational, longitudinal design which will permit the evaluation of benefit over time for individual patients, groups of patients and the evaluation of the benefit in terms of service based outcomes of the redevelopment of a complete National Forensic Mental Health Service e.g. effects on waiting list times, length of stay. The study will systematically evaluate multiple domains of recovery in a complete National Forensic Service, including patients' physical health, mental health, offending behaviours and social and occupational functioning.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Length of stay in the secure forensic hospital setting. (5 years)
  • Recovery from psychosis (5 years)
  • Reduction in violence (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-12-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Health Service Executive, Ireland
Principal Investigators:
  • Mary Davoren, M.D. (PRINCIPAL_INVESTIGATOR) - Trinity College University of Dublin
Contact Information
Study Contact:
Mary Davoren, M.D.
0035312157401
davorem@tcd.ie
Harry G Kennedy, M.D.
0035312157400
kennedh@tcd.ie
Mary Davoren, M.D.
0035312157401
davorem@tcd.ie
National Forensic Mental Health Service, Central Mental Hospital
Interventions
N/A
Study Locations (1 sites)
National Forensic Mental Health Service, Central Mental Hospital, Dublin, D14 W0V6 Ireland
Eligibility Criteria
Inclusion Criteria: * Admitted to the National Forensic Mental Health Service (NFMHS) Ireland after 1st December 2019 until 7 years after the transfer of the National Service to the newly developed complete National Forensic Service at Portrane, North Dublin, Ireland. Exclusion Criteria: * This study comprises a complete cohort of admissions to the NFMHS. All adult patients admitted during the time period will be included in the study, regardless of their length of stay.

Family Model DSME in FBOs in the RMI

NCT05502016
Recruiting
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 288
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Health disparities in the Republic of the Marshall Islands are striking, with extremely high rates of type 2 diabetes. Documented prevalence of type 2 diabetes in the Marshall Islands ranges from 20%-50%.This is significantly higher than the global (8.5%) and United States (11%) prevalence. Diabetes doubles the risk of heart disease; is the leading cause of kidney failure, lower limb amputation, and acquired blindness; and reduces life expectancy by as much as 15 years. Diabetes self-management education and support is critical for persons with diabetes. This study aims to conduct a cluster-randomized controlled trial using a wait-list control to evaluate the effectiveness of family model diabetes self-management education and support when delivered in faith-based organizations (i.e., churches) in Marshallese by trained community health workers. The study will be conducted with up to 288 participants with type 2 diabetes and up to 288 of their family members. The primary study outcome will be glycemic control as measured by HbA1c. Secondary biometric measures include: fasting glucose, weight, body mass index, and blood pressure. Survey data will be collected pre-intervention, immediately post-intervention, four months post-intervention, and 12 months post-intervention for the intervention arm of the study. The control arm of the study will have two pre-intervention data collections before beginning the intervention. Data will then be collected from the control group immediately post-intervention, four months post-intervention, and 12 months post intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Family Model Diabetes Self-Management Education and Support — Participants assigned to this arm receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
  • Behavioral: Family Model Diabetes Self-Management Education and Support (Wait-list) — Participants assigned to this arm will wait approximately 12 weeks to receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.

Primary Outcomes

  • Glycemic control, measured by change in mean HbA1c (%) from baseline (Baseline, Immediate post-intervention, 4 months post-intervention, 12 months post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-30
Completion: 2027-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 288 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Arkansas
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Pearl McElfish, PhD (PRINCIPAL_INVESTIGATOR) - University of Arkansas
Contact Information
Study Contact:
Betsy O'Connor, MA
479-713-8000
geoconnor@uams.edu
Brett Rowland, MA
479-713-8000
mbrowland@uams.edu
Alix Montoya-Beltran
479-713-8000
amontoyabeltran@uams.edu
UAMS Institute for Community Health Innovation
Interventions
  • Behavioral: Family Model Diabetes Self-Management Education and Support — Participants assigned to this arm receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
  • Behavioral: Family Model Diabetes Self-Management Education and Support (Wait-list) — Participants assigned to this arm will wait approximately 12 weeks to receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
Study Locations (1 sites)
UAMS Institute for Community Health Innovation, Springdale, Arkansas 72764 United States
Eligibility Criteria
Inclusion Criteria: * self-reported Marshallese * 18 years of age or older * have type 2 diabetes (defined as having HbA1c equal to or greater than 6.5%) * have at least one family member willing to take part in the study Exclusion Criteria: * has received diabetes self-management education in the past five years * has a condition that makes it unlikely that the participant will be able to follow the protocol, such as terminal illness, non-ambulatory, severe mental illness, severely impaired vision or hearing, eating disorder * plans to move out of the geographic region
Conditions Diabetic Kidney Disease
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

With the rapid increase of diabetic nephropathy worldwide, type 2 diabetes mellitus(DM) is the leading cause of end-stage renal disease(ESRD). Pathological types of diabetic kidney disease(DKD) could be mainly divided into diabetic nephropathy(DN)and non-diabetic renal diseases(NDRD). There are no accurate renal biopsy indications and standardized operation procedures for type 2 diabetic nephropathy. The clinical stages of type 2 diabetic nephropathy still referred to the Mogensen stage of type 1 diabetic nephropathy. Thus, our study aim to clarify the differences in clinical phenotype between type 2 DN and type 2 NDRD, analysis the correlation between clinical and pathological features, and offer the criteria for clinical staging and prognosis.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • change in eGFR and urine protein from baseline (24months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2017-11-30
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese PLA General Hospital
Collaborators: Beijing Municipal Science & Technology Commission, China-Japan Friendship Hospital, Beijing Friendship Hospital, Beijing Hospital, Fourth Medical Center of PLA General Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Third Medical Center of Chinese PLA General Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, The First Affiliated Hospital of Dalian Medical University, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Dongzhimen Hospital, Beijing, Shanghai University of Traditional Chinese Medicine
Principal Investigators:
  • Xiangmei Chen, MD.&Ph.D (PRINCIPAL_INVESTIGATOR) - Chinese PLA General Hospital
Contact Information
Study Contact:
Xiangmei Chen, MD.&Ph.D
+86 010 66935462
xmchen301@126.com
Zheyi Dong, MD.&Ph.D
+86 010 66935462
shengdai26@163.com
Xiangmei Chen, MD.&Ph.D
+86 010 66935462
xmchen301@126.com
Chinese PLA General Hospital
Interventions
N/A
Study Locations (1 sites)
Chinese PLA General Hospital, Beijing, Beijing Municipality 100853 China
Eligibility Criteria
Inclusion Criteria: * Age≥18, male or female * Clinical diagnosed as type 2 diabetes mellitus * The presence of renal impairment including: microalbuminuria or overt proteinuria or renal insufficiency * The renal biopsy was performed with complete renal pathological diagnosis * Obtaining the signed informed consent from patients Exclusion Criteria: * The history of the disease was not complete * Clinical diagnosed as other secondary renal diseases * Patients with hereditary kidney disease * Autoimmune diseases * Patients with malignant tumor were expected to survive less than 6 months * Pregnancy and lactation
Conditions Gestational Diabetes Mellitus (GDM), Dia...
Phase Not Applicable
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

The investigators will use implementation methods to develop better breastfeeding support for patients with gestational diabetes as a way to prevent type 2 diabetes.

Design

Study type: Observational Observational model: Other Time perspective: Other

Interventions / Regimen

  • Other: Implementation mapping to develop a multilevel health system strategy for prevention of type 2 diabetes through targeted breastfeeding support for patients with gestational diabetes — Conduct implementation mapping to develop a multilevel health system breastfeeding support strategy for patients with GDM at UC Davis Health in Sacramento, California, a large academic medical center. The study design for this mapping process will include five steps in this 1-year proposal: (1) conduct a needs and assets assessment and identify implementers; (2) identify implementation outcomes and determinants; (3) choose mechanisms of change and design implementation strategies; (4) produce implementation protocols and materials; and prepare for the final step, (5) evaluate implementation outcomes, by selecting outcome measures for a future trial . This disciplined and systematic approach to intervention development will directly inform my future directions: a mixed methods feasibility trial to pilot the implementation strategy developed here, followed by a full-scale randomized trial to test the strategy's effectiveness in reducing diabetes risk.

Primary Outcomes

  • Design novel implementation strategies for future mixed method trial (September 2026)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-23
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Davis
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Adrienne Hoyt-Austin, DO, MAS, IBCLC (PRINCIPAL_INVESTIGATOR) - UC Davis Health
Contact Information
Study Contact:
Adrienne Hoyt-Austin, DO, MAS, IBCLC
916-734-4580
aehoyt@health.ucdavis.edu
Elva T Horath, MD
510-910-4443
ethorath@health.ucdavis.edu
Elva Horath, MD
UC Davis Medical Center
Interventions
  • Other: Implementation mapping to develop a multilevel health system strategy for prevention of type 2 diabetes through targeted breastfeeding support for patients with gestational diabetes — Conduct implementation mapping to develop a multilevel health system breastfeeding support strategy for patients with GDM at UC Davis Health in Sacramento, California, a large academic medical center. The study design for this mapping process will include five steps in this 1-year proposal: (1) conduct a needs and assets assessment and identify implementers; (2) identify implementation outcomes and determinants; (3) choose mechanisms of change and design implementation strategies; (4) produce implementation protocols and materials; and prepare for the final step, (5) evaluate implementation outcomes, by selecting outcome measures for a future trial . This disciplined and systematic approach to intervention development will directly inform my future directions: a mixed methods feasibility trial to pilot the implementation strategy developed here, followed by a full-scale randomized trial to test the strategy's effectiveness in reducing diabetes risk.
Study Locations (1 sites)
UC Davis Medical Center, Sacramento, California 95817 United States
Eligibility Criteria
Inclusion Criteria: * ≥18 years old and able to communicate in English * Fits into one of the following: 1. patients with GDM who are recently pregnant and/or postpartum; 2. health care providers (nurses, physicians, lactation consultants, etc.) who would implement the strategy 3. executive leadership Exclusion Criteria: * Subjects not meeting the inclusion criteria will be considered ineligible for participation
Conditions Type 2 Diabetes
Phase PHASE1
Enrollment 29
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

To examine the 2-HIT hypothesis that the SGLT2i-induced stimulation of EGP, lipolysis, and ketone production requires the combination of volume depletion plus insulinopenia in T2D individuals.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: Empagliflozin 25 MG — A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.

Primary Outcomes

  • Ketone Body Turnover (ketogenesis) (0 and 300 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-04-29
Completion: 2027-06-30
Eligibility
Age: 30 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 29 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center at San Antonio
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Ralph DeFronzo, MD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center at San Antonio
Contact Information
Study Contact:
Ralph DeFronzo, MD
210-567-6691
defronzo@uthscsa.edu
Aurora Merovci, MD
210-567-6691
merovci@uthscsa.edu
Ralph DeFronzo, MD
210-358-7200
defronzo@uthscsa.edu
Texas Diabetes Institute/UH
Interventions
  • Drug: Empagliflozin 25 MG — A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
Study Locations (1 sites)
Texas Diabetes Institute/UH, San Antonio, Texas 78229-3900 United States
Eligibility Criteria
Patients with T2D Inclusion Criteria: * Ages 30-75 * BMI (Body Mass Index) 21-45 kg/m2 * HbA1c = 7.0-11% * eGFR (estimated glomerular filtration rate)\> 60 ml/min/1.73m2 * Blood Pressure (BP)≤160/90 mmHg * Participants must be in general good health based on medical history, physical exam, screening blood chemistries, CBC (Complete Blood Count), TSH/T4 (thyroid/thyroxine hormone), EKG (electrocardiogram), and urinalysis (UA) * Stable body weight (±1.5 kg) over the last 3 months and must not participate in an excessively heavy exercise program * Patients treated with diet, Sulfonylureas, Metformin, or Sulfonylureas/Metformin (Sulfo/MET) * Participants receiving a Glucagon like peptide -1 receptor agonist (GLP1-RA) must be on a stable dose for at least three months prior to study enrollment. * Participants receiving a Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitor) must be on a stable dose for at least two months prior to study enrollment. * SGLT2 inhibitors must be discontinued at least two months prior to study enrollment. * Statin therapy is permissible if the dose has been stable for at least 3 months EXCLUSION CRITERIA An individual who meets any of the following criteria will be excluded from participation in this study: * Patients treated with Thiazolidinediones (TZDs), or Insulin are excluded. * Patients taking medications other than Sulfonylureas/Metformin (SU/MET), stable dose of GLP1-RA and DPP4i known to affect glucose metabolism are excluded. Patients taking SGLT2i within 2 months of screening visit will be excluded from participating in this study, however they may be asked whether they would agree to discontinue the medication for two months to become eligible. (Please see clarification below.) \* * Subjects with evidence of proliferative retinopathy or estimated glomerular filtration rate (eGFR) \< 60 are excluded * Women of childbearing potential are excluded unless they are taking/using appropriate contractive medications/devices \* Only participants who are taking SGLT2 inhibitors during the prescreening period will be asked to discontinue the medication at least two months prior to the screening visit. If they agree, they will return for an HbA1c measurement four weeks after stopping the SGLT2 inhibitor. If their HbA1c rises to greater than 10%, treatment will be initiated with either metformin, a DPP-4 inhibitor, or a sulfonylurea. We do not anticipate any adverse effects during this initial period, provided the HbA1c remains below 10%. HbA1c will be measured using a fingerstick test, which requires only a minimal amount of blood. No compensation will be provided during this phase. After two months of medication discontinuation, participants will return for a screening visit. If they meet all eligibility criteria, they will be enrolled in the study and payment done by protocol.
Conditions Type 2 Diabetes, Inflammation, Insulin S...
Phase NA
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Every 3 minutes a new case of diabetes is diagnosed in Canada, mostly type 2 diabetes (T2D) increasing the risk for heart disease. T2D and heart disease share many common risk factors such as aging, obesity and unhealthy lifestyle. Paradoxically however, while lowering blood LDL, commonly known as "bad cholesterol", is protective against heart disease, research over the past 10 years have shown that the lower is blood LDL, the higher is the chance of developing T2D. This phenomena is happening whether blood LDL is lowered by a common drug against heart disease called Statins, or by being born with certain variations in genes, some of which are very common (\~80% of people have them). To date, it is unclear why lowering blood LDL is associated with higher risk for diabetes, and whether this can be treated naturally with certain nutrients. Investigators believe that lowering blood LDL by forcing LDL entry into the body tissue through their receptors promotes T2D. This is because investigators have shown that LDL entry into human fat tissue induces fat tissue dysfunction, which would promote T2D especially in subjects with excess weight. On the other hand, investigators have shown that omega-3 fatty acids (omega-3) can directly treat the same defects induced by LDL entry into fat tissue. Omega-3 is a unique type of fat that is found mostly in fish oil. Thus the objectives of this clinical trial to be conducted in 48 subjects with normal blood LDL are to explore if: 1. Subjects with higher LDL receptors and LDL entry into fat tissue have higher risk factors for T2D compared to subjects with lower LDL receptors and LDL entry into fat tissue 2. 6-month supplementation of omega-3 from fish oil can treat subjects with higher LDL receptors and LDL entry into fat tissue reducing their risk for T2D. This study will thus explore and attempt to treat a new risk factor for T2D using an inexpensive and widely accessible nutraceutical, which would aid in preventing T2D in humans.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Omega-3 fatty acids — Triple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)

Primary Outcomes

  • Fasting white adipose tissue NLRP3 inflammasome activation (Baseline)
  • Fasting white adipose tissue NLRP3 inflammasome activation (At 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-12-19
Completion: 2027-05-31
Eligibility
Age: 45 Years – 74 Years
Sex: ALL
Volunteers: true
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut de Recherches Cliniques de Montreal
Collaborators: Canadian Institutes of Health Research (CIHR)
Principal Investigators:
  • May Faraj, PDt, PhD (PRINCIPAL_INVESTIGATOR) - Montreal Clinical Research Institute/ University of Montreal
Contact Information
Study Contact:
Justine Fricher, MSc
514-987-5500
justine.fricher@ircm.qc.ca
Rianne Mahiout, BSc
514-987-5500
rianne.mahiout@ircm.qc.ca
Justine Fricher, MSc
514-987-5500
justine.fricher@ircm.qc.ca
Montreal Clinical Research Institute
Interventions
  • Dietary Supplement: Omega-3 fatty acids — Triple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)
Study Locations (1 sites)
Montreal Clinical Research Institute, Montreal, Quebec H2W 1R7 Canada
Eligibility Criteria
Inclusion Criteria: Men and post-menopausal women: * Having a body mass index (BMI= 25-40 kg/m2) * Aged between 45 and 74 years * Having confirmed menopausal status (FSH ≥ 30 U/l) * Non-smoker * Sedentary (less than 2 hours of structured physical exercise (ex: sports club) per week) * Low alcohol consumption: less than 2 alcoholic drinks/day Exclusion Criteria: * Plasma LDL cholesterol \> 3.5 mmol/L (i.e. \> 75th percentile in a Canadian population). * Elevated risk of cardiovascular disease (≥ 20% of calculated Framingham Risk Score) who would require immediate medical intervention by lipid-lowering agents. * Prior history of cardiovascular events (like stroke, transient ischemic attack, myocardial infarction, angina, heart failure…) * Systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg * Type 1 or 2 diabetes or fasting glucose \> 7.0 mmol/L * Prior history of cancer within the last 3 years * Thyroid disease - untreated or unstable * Anemia - Hb \< 120 g/L * Renal dysfunction or plasma creatinine \> 100 µmol/L * Hepatic dysfunction - AST/ALT \> 3 times normal limit * Blood coagulation problems (i.e. bleeding predisposition) * Autoimmune and chronic inflammatory disease (i.e. celiac, inflammatory bowel, Graves, multiple sclerosis, psoriasis, rheumatoid arthritis, and lupus).Known history of difficulties accessing a vein * Claustrophobia * Sleep apnea * Seizures * Concomitant medications: Hormone replacement therapy (except thyroid hormone at a stable dose), systemic corticosteroids, anti-psychotic medications and psycho-active medication, anticoagulant or anti-aggregates treatment (Aspirin, NSAIDs, warfarin, coumadin..), adrenergic agonist, anti-hypertensive drugs, weight-loss medication, lipid lowering medication * Known substance abuse * Already taking more than 250 mg of omega-3 supplements (EPA/DHA) per day * Allergy to seafood or fish * Allergy to Xylocaine * Unable to eat the components of the high fat meal (croissant, cheese, bacon, brownies) * None compliance to the study requirements (i.e. not being fasting) or cancellation of the same scheduled testing visit more than once. * Lack of time to participate in the full length of the study (33 weeks) * Have exceeded the annual total allowed radiation dose (like X-ray scans and/or tomography in the previous year or in the year to come) according to the physician's judgement. * All other medical or psychological conditions deemed inappropriate according to the physician
Conditions Moderate to Severe Asthma
Phase PHASE3
Enrollment 230
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week double-blind randomized treatment period, and a 12-week safety follow-up period.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: CM326 — subcutaneous injection
  • Other: Placebo — subcutaneous injection

Primary Outcomes

  • Annualized rate of severe asthma exacerbations at Week 52 (week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-01-23
Completion: 2029-03-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 230 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Contact Information
Study Contact:
Clinical Trials Information Group officer
031169085587
ctr-contact@cspc.cn
Jie Ming Qu, PHDD
18901661180
jmqu0906@163.com
Ruijin Hospital, Shanghai Jiao tong University School of Medicine
Interventions
  • Drug: CM326 — subcutaneous injection
  • Other: Placebo — subcutaneous injection
Study Locations (1 sites)
Ruijin Hospital, Shanghai Jiao tong University School of Medicine, Shanghai, Shanghai Municipality 200000 China
Eligibility Criteria
Inclusion Criteria: 1. Understand the study and voluntarily sign the informed consent form. 2. Age ≥18 and ≤80 years old, male or female, weight ≥40 kg. 3. The subject has been diagnosed with asthma for at least 1 year. 4. Pre-bronchodilator FEV1 measured ≤80% of the normal predicted value. 5. A positive bronchodilation test within 24 months before informed consent or at screening. 6. The subject has received medium-to-high dose ICS combined with at least one control drug, such as LABA, LAMA, LTRA, Oral corticosteroids, theophylline, for at least 3 months before signing the informed consent, and maintained stable treatment regimen and dosage for at least 1 month before signing the informed consent. 7. Asthma Control Questionnaire-5 (ACQ-6) score ≥1.5. 8. Subjects must have experienced at least one severe asthma exacerbation event within 12 months before informed consent, and have not experienced a severe asthma exacerbation event within 30 days before informed consent. 9. ≥ 80% compliance with usual asthma controller therapy in subjects during the screening phase 10. Voluntarily use highly effective contraception from the time of signing the informed consent form until 3 months after the last dose. Exclusion Criteria: 1. Chronic obstructive pulmonary disease (COPD) without asthma or other lung disease that may impair lung function, as judged by the investigator. 2. Have systemic diseases other than asthma that result in an elevated peripheral blood eosinophil count or other diseases such as helminth parasitic infections for which standard treatment is not received or does not respond. 3. Prior autoimmune disease or inflammatory treatment with biologic agents/systemic immunosuppressive agents within 8 weeks or 5 half-lives (whichever is longer) prior to informed consent. 4. Previous history of known or suspected immunosuppression, including a history of invasive opportunistic infection, even if the infection has resolved; or the presence of unusual frequent, recurrent, or prolonged infections. 5. History of malignancy. 6. The presence of any severe and/or uncontrolled medical condition that in the judgment of the investigator may affect the evaluation of the drug, including but not limited to: severe neurological disease, history of severe mental disorder, diabetes mellitus poorly controlled by intensive treatment. 7. Active infection or acute infection requiring systemic anti-infective therapy from 4 weeks before enrollment to the time of randomization. 8. A history of severe cardiovascular disease or clinically significant abnormalities identified by 12-lead electrocardiogram (ECG) during the screening phase. 9. Major surgery within 8 weeks prior to informed consent requiring general anesthesia or hospitalization for \> 1 day . 10. Received biological agents with the same therapeutic purpose within 4 months or 5 half-lives (whichever is longer) before signing the informed consent. 11. Have been enrolled in a clinical trial of any drug or medical device within 3 months before signing informed consent, or are within the follow-up period of a clinical study or the five half-lives of the trial drug (whichever is longer) before signing informed consent. 12. Received immune globulin or blood products within 30 days before informed consent. 13. Subjects treated with systemic corticosteroids other than for the treatment of asthma from 8 weeks before signing the informed consent to the date of randomization. 14. Received live or attenuated vaccine within 3 months before informed consent. 15. Initiation of desensitization therapy within 3 months before informed consent. 16. Underwent bronchial thermoplasty within 12 months before informed consent. 17. Current smokers or former smokers who quit smoking less than 6 months or former smokers who quit smoking more than 6 months with a smoking history of more than 10 pack-years. 18. At screening, any infectious disease screening indicator meets one of the following criteria: a. HBsAg positive b. HBsAg negative , HBcAb positive, HBV DNA exceed the lower limit of quantitation (LLOQ) or 1000 copies/mL (500 IU/mL)(whichever is lower) c. HCV antibody positive, HCV RNA exceed the LLOQ or 1000 copies/mL(whichever is lowerd). d.HIV antibody positive. e.Treponema pallidum antibody positive 19. At screening, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2 × upper limit of normal (ULN), or serum creatinine (Cr) \> 1.5 × ULN. 20. Allergy or intolerance to components of CM326 injection or placebo or history of severe drug allergy or anaphylactic shock. 21. Subjects who have used heavy alcohol within 3 months before screening. 22. History of drug abuse within 5 years before signing informed consent. 23. Females with a positive pregnancy test, pregnant females, or lactating females. 24. The investigator considers that there are any conditions that may prevent the subject from completing the study.
Conditions Asthma in Children
Phase NA
Enrollment 18
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

While single maintenance and reliever therapy (SMART) has been the preferred management strategy for Step 3 and 4 (moderate/severe) asthma management since the 2020 NIH asthma guideline updates, adoption of SMART has not been rigorously assessed. This study will test electronic medical record clinical decision support and education implementation strategies (CDS+) to increase adoption of SMART in pediatric primary care. This is the first of two related records.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Clinical decision support + education (CDS+) — Intervention clinic providers will experience nudges in the electronic medical record to encourage prescribing SMART where clinically-appropriate and intervention clinic providers, families/patients, and nurses will receive education (collectively CDS+).
  • Other: Control — Clinics in Arm 2 will not be exposed to the interventions.

Primary Outcomes

  • Change in the Rate of Visit-Level SMART Adoption (Assessment of rates from two study intervals: Interval 0 (baseline; 11 months), Interval 1 (CDS+; 11 months). There will be a one month ramp up period at the start of each study interval (ramp up period data will not be included in analyses).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-03
Completion: 2028-02-29
Eligibility
Age: 5 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 18 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital of Philadelphia
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Contact Information
Study Contact:
Chén Kenyon, MD, MSHP
267-426-6339
kenyonc@chop.edu
Chén Kenyon, MD, MSHP
267-426-6339
kenyonc@chop.edu
Children's Hospital of Philadelphia
Interventions
  • Behavioral: Clinical decision support + education (CDS+) — Intervention clinic providers will experience nudges in the electronic medical record to encourage prescribing SMART where clinically-appropriate and intervention clinic providers, families/patients, and nurses will receive education (collectively CDS+).
  • Other: Control — Clinics in Arm 2 will not be exposed to the interventions.
Study Locations (1 sites)
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Clinic Inclusion Criteria: * The clinic is a pediatric primary care clinic that is part of the Children's Hospital of Philadelphia (CHOP) Pediatric Research Consortium (PeRC). * The clinic agrees to participate in SMART \& SIMPLE study. Patient Inclusion Criteria: * Ages 5-18 years; * Has clinic visit at participating practice during study interval (sick, well, or follow-up) * Prescribed at least one prescription for an inhaled corticosteroid (ICS) or ICS-long-acting beta agonist (ICS-LABA) for maintenance asthma therapy in the past year; * Evidence of uncontrolled asthma as determined by: (1) uncontrolled Asthma Control Tool score in the past 6 months OR (2) two or more systemic corticosteroids prescribed for an asthma exacerbation in the past 12 months (one occurring in the past 6 months) Clinic Exclusion Criteria: \- The clinic is not willing to participate in SMART \& SIMPLE study interventions. Patient Exclusion Criteria: \- Transferred clinics or left the CHOP Pediatric Care Network.
Conditions Pulmonary Disease, Asthma
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective multi-centers cohort study for registration adult patients with severe asthma and were reimbursed biologics treatment in Taiwan. The goal of this observational study is to discover the real-world effectiveness, the impact of initiating, switching of biologics, and the possible prediction factors for selecting the best treatment option for patients. The main question\[s\] it aims to answer are: 1. Determine risk factors associated with poor asthma control. 2. Support the development of effectiveness and safety of therapeutic principles 3. To discover the real-world effectiveness of different biologics ( Clinical remission) 4. To discover the impact of initiating biologics for severe asthma patients. 5. To evaluate the prevalence of biologics switching and its benefits for patients. 6. To compare the achievement rate of clinical remission among different biologics. Participants who are treated either with omalizumab, mepolizumab, benralizumab dupilzumab or Tezepelumab after January 1, 2020 will be included in the study.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Biological: Biological Treatment for severe asthma patients — Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance

Primary Outcomes

  • Status of Asthma Control (6 months)
  • Status of Asthma exacerbations (6 months)
  • Reduction of daily oral corticosteriod dose (6 months)
  • Change of Pre-BD FEV1 (%pred) (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-11
Completion: 2043-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Taichung Veterans General Hospital
Collaborators: E-DA Hospital, National Cheng-Kung University Hospital, National Yang Ming Chiao Tung University Hospital, Chang Gung Memorial Hospital
Contact Information
Study Contact:
Pin-Kuei Fu, MD.,PhD.
886-4-23592525
yetquen@gmail.com
Pin-Kuei Fu, MD, PhD
886-4-23592525
yetquen@gmail.com
Taichung Veterans General Hospital
Interventions
  • Biological: Biological Treatment for severe asthma patients — Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance
Study Locations (1 sites)
Taichung Veterans General Hospital, Taichung, 40705 Taiwan
Eligibility Criteria
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures. * Patient should be reviewed as well as confirmed by the National Health Insurance Administration (NHIA) or by the study board member as a Severe Asthma case. * Female and male aged over 18 years old. * Patients who are treated either with omalizumab, mepolizumab, or benralizumab after January 1, 2020. Exclusion Criteria: * Lack of informed consent for participation. * History of Biologic usage before January 1, 2020, should be ruled out. * The washout period should be at least 12 months. In other words, the enrolled patients should have no experience in receiving a biological treatment or in participating relative clinical trial before his/her biologic initiation. * Comorbid pulmonary diseases (e.g.: Chronic Obstructive Pulmonary Disease, Bronchiectasis, Pulmonary Fibrosis, etc.) or risk factors (e.g.: smoking or environmental exposure, etc..) that could be associated with pulmonary or systemic diseases, other than Asthma.